

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Evaluation of capillary pathologies by nailfold capillaroscopy in patients with psoriasis vulgaris: Study protocol for a prospective, controlled, clinical trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021595
Article Type:	Protocol
Date Submitted by the Author:	09-Jan-2018
Complete List of Authors:	Fink, Christine; University Hospital Heidelberg, Department of Dermatology Bertlich, Ines; University Hospital Heidelberg, Department of Dermatology Hoxha, Elti; University Hospital Heidelberg, Department of Dermatology Enk, Alexander; University Hospital Heidelberg, Department of Dermatology Haenssle, Holger; University Hospital Heidelberg, Department of Dermatology
Keywords:	Psoriasis < DERMATOLOGY, nailfold capillaroscopy, capillary pattern, capillary morphology

SCHOLARONE™  
Manuscripts

Peer Review Only

1  
2  
3 **Evaluation of capillary pathologies by nailfold capillaroscopy in patients with psoriasis**  
4 **vulgaris: Study protocol for a prospective, controlled, clinical trial**  
5  
6  
7  
8  
9  
10

11 **Authors:**

12 Christine Fink<sup>1</sup>, Ines Bertlich<sup>1</sup>, Elti Hoxha<sup>1</sup>, Alexander Enk<sup>1</sup>, Holger A Haenssle<sup>1</sup>  
13  
14  
15

16  
17  
18  
19 **Departments/Institutions:**  
20

21 <sup>1</sup>Department of Dermatology, University of Heidelberg, Germany  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 **Word count:** 1565  
37  
38  
39  
40

41 **Corresponding Author:**

42 Prof. Dr. med. Holger A. Haenssle  
43

44 Department of Dermatology, University of Heidelberg,  
45

46 Im Neuenheimer Feld 440, 69120 Heidelberg  
47

48 Holger.Haenssle@med.uni-heidelberg.de  
49

50 Fon: +49-6221-56-39555  
51

52 Fax: +49-6221-56-4996  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

### Introduction

Psoriasis vulgaris was shown to be an independent factor increasing the risk of several comorbidities such as obesity, diabetes and dyslipidemia with an increased risk of stroke and myocardial infarction. We hypothesize that early endothelial dysfunction, which plays a crucial role in the pathogenesis of atherosclerosis, may be detected by digital video nailfold capillaroscopy (DVNC) at the level of the dermal capillary microvasculature as a surrogate parameter. Nailfolds represent the only body site allowing for a non-invasive assessment of the capillary microvasculature at a horizontal plane. DVNC is a well-established diagnostic tool for in-vivo assessment of the peripheral microcirculation by evaluating the morphology of dermal papillary capillaries. To date, reports on morphological changes of the non-lesional nailfold capillaries in patients with psoriasis vulgaris are scarce and the existing data is not conclusive.

### Methods and analysis

This is a prospective, single center, non-randomized, controlled pilot study assessing the capillary patterns in 75 subjects affected by psoriasis vulgaris. Non-lesional nailfold capillaries will be imaged by means of DVNC (Optilia Digital Capillaroscopy System, Optilia Instruments AB, Sollentuna, Sweden) in 50 patients affected by psoriasis vulgaris and 25 healthy controls. Assessments will include a qualitative, descriptive analysis of the nailfold capillaries' morphology, as well as a quantitative investigation (frequency, extent) of changes in capillary patterns. Moreover, patients' characteristics associated with the manifestation of nailfold capillaries' pathologies including well-known cardiovascular risk markers will be studied.

### Ethics and dissemination

Ethical approval was provided by the ethic committee of the medical faculty of the University of Heidelberg (Ethics approval number S-447/2017). The design and the final results of the study will be published and made available to the public.

### **Study registration**

This study is registered at the German Clinical Trial Register (DRKS): DRKS00012856

## **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- This pilot study addresses important open questions concerning the use of nailfold capillaroscopy as a surrogate parameter for determining the extent of endothelial dysfunction in psoriasis patients.
- After confirmation by an additional larger clinical trial, non-invasive digital nailfold capillaroscopy in psoriasis patients may help to facilitate the identification of patients at increased risk for development of cardiovascular disease.
- Since this is a pilot study, limitations arise from the single-site setting and the small number of subjects in both groups.

## INTRODUCTION

Digital video nailfold capillaroscopy (DVNC) is routinely used for in-vivo assessment of the peripheral microcirculation by evaluating the morphology of dermal papillary capillaries [1]. Long before onset of clinical symptoms pathological capillary patterns may be observed in a number of systemic diseases, which are accompanied by vascular damage. Therefore, DVNC might be helpful to define surrogate parameters indicative of initial manifestation of cardiovascular disease [2]. Additionally, capillary abnormalities were shown to potentially reflect the severity and long-term prognosis of underlying diseases. For instance, in systemic sclerosis an association between a decreased capillary density and the development and the severity of pulmonary arterial hypertension was detected [3]. Psoriasis vulgaris is a common chronic skin disease which is accompanied by a number of comorbidities, that are possibly induced by a chronic, low-grade, systemic inflammation leading to vascular insufficiency and finally to clinically relevant atherosclerosis [2,4,5]. Atherosclerosis in psoriasis patients was shown to be caused by a transfer of inflammatory cells and cytokines from the skin to endothelial tissue and internal organs causing systemic inflammation [2,5,6]. Endothelial dysfunction is often used as a surrogate marker for atherosclerosis and several studies have shown impaired endothelial function in patients with moderate to severe psoriasis or psoriatic arthritis [2,6,7]. Besides broad evidence for an increased risk of large vessel atherosclerosis, previous studies also indicated changes of the microvasculature in the papillary dermis of psoriatic plaques and the synovia of psoriatic joints [8,9]. However, until today only little is known about changes in the microcirculation in non-lesional skin of psoriasis patients. The reported data are controversial with regard to pathologies of nailfold capillaries, which most probably reflects the polyetiology and polymorphology of psoriasis. In one of the earliest studies Redisch et al. revealed tortuous capillaries with tight terminal convolutions in lesional and non-lesional skin of psoriasis patients [10]. A decreased capillary density, shorter

1  
2  
3 capillaries, more nailfold hemorrhages and sluggish blood flow in patients with psoriasis  
4 arthritis were observed by Zaric et al. when compared to healthy controls [11]. A pattern with  
5 shorter and more tortuous capillaries was significantly correlated with periungual psoriatic  
6 plaques, nail pitting, onycholysis, and the extent of the involved body surface in a study by  
7 Ohtsuka et al. [12]. A study by Ribeiro et al. showed a lower capillary density, increased  
8 avascular areas and an increased number of coiled capillaries in the nailfold of patients with  
9 psoriasis [13]. Finally, Bushan et al. reported a significantly decreased capillary loop density  
10 and a reduction of arterial and venous capillary limb diameters but found no other of the  
11 previously described morphological abnormalities in any of the patients [14].

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22 The aim of our study is to gather further evidence concerning the morphology, frequency and  
23 the extent of nailfold capillary changes in patients with psoriasis vulgaris and to identify  
24 patient characteristics possibly associated with specific pathological DVNC patterns.  
25  
26  
27  
28  
29  
30

## 31 **DESIGN/METHODS**

### 32 33 34 **Study design and objectives**

35  
36  
37 This is a prospective, single center, non-randomized, controlled pilot study assessing the  
38 capillary patterns in 75 individuals by means of DVNC. The primary objective of this study is  
39 to investigate the frequency, the extent, and the morphology of changes in capillary patterns  
40 in 50 patients that are either affected by psoriasis vulgaris alone (group A) or by psoriasis  
41 vulgaris in combination with accompanying psoriasis arthritis (group B) compared to 25  
42 healthy subjects (group C) (Fig. 1). A secondary objective of this study is to identify patient  
43 characteristics that are statistically associated with specific DVNC patterns (e.g. psoriasis  
44 severity, nail psoriasis, age, gender, duration of the disease, manifest cardiovascular diseases  
45 and circulating markers of endothelial damage and inflammation).  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

### 57 **Criteria for inclusion/exclusion**

1  
2  
3 Inclusion criteria for group A and B are: patients  $\geq 18$  and  $\leq 80$  years of age with the diagnosis  
4 of chronic moderate to severe plaque psoriasis (defined as involved BSA  $\geq 10\%$  and PASI  
5 score  $\geq 10$  and DLQI  $\geq 10$ ) with or without psoriatic arthritis for at least 6 months (duration  
6 since diagnosis may be reported by the patient). Exclusion criteria for group A and B are:  
7 patients under current exposure to any anti-psoriatic or immunosuppressive systemic therapy  
8 (discontinuation for at least 4 weeks prior to DVNC is mandatory), patients with any other  
9 skin disease or therapy affecting the area of interest for DVNC and subjects with non-plaque  
10 forms or drug-induced psoriasis as well as active ongoing inflammatory diseases other than  
11 psoriasis that might confound study evaluations. Inclusion criteria for group C (healthy  
12 subjects) are: patients  $\geq 18$  and  $\leq 80$  years of age with no skin disease and no inflammatory  
13 rheumatic disease. Patients with any skin disease affecting the area of interest for DVNC or  
14 any active ongoing inflammatory diseases that might confound study evaluations will be  
15 excluded. Patients will be excluded from all three groups if any cosmetic procedure involving  
16 the nailfold area was performed over the last 4 weeks since potential micro-traumata may lead  
17 to false-positive results in DVNC [15, 16].  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

## 36 **Methods**

37  
38  
39 In this study the nailfold capillaries of 75 individuals will be evaluated by DVNC (Optilia  
40 Digital Capillaroscopy System, Optilia OP-120 021, Optilia Instruments AB, Sweden) (Fig.  
41 1). DVNC will be performed with low magnification (x20; for global evaluation of the entire  
42 nailfold area) and high magnification (x200; for more detailed observations of separate  
43 capillaries). Nailfolds of the 2nd to the 5th finger of both hands will be examined. For the  
44 high magnification setting a total of 32 pictures (4 consecutive images per nailfold, each  
45 covering 1 mm) will be taken [15, 16]. For standardization and quality assurance the DVNC is  
46 performed after 15–20 min of acclimatization at room temperature in a sitting position.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56 Smoking and caffeinated beverages should be avoided at least four hours before DVNC to  
57  
58  
59



avoid capillary constriction. In our study a semiquantitative image analysis based on the microangiopathy evolution score presented by Cutolo et al. will be applied [15]. The intra- and inter-rater reliability of this semiquantitative scoring-algorithm has been demonstrated [17]. Several capillaroscopic parameters will be evaluated and scored, e.g. presence of enlarged (>20  $\mu\text{m}$  loop diameter) and giant capillaries (loop diameter > 50  $\mu\text{m}$ ), hemorrhages and/or hemosiderin deposits, capillary loss (< 9-10 capillaries per linear mm counted at the distal row of the nailfold), disorganization of the vascular array (distribution and orientation) and ramified capillaries/neoangiogenesis (tortuous, branching, bushy, coiled) (Table 1). Optionally, further morphological characteristics may be described. To evaluate patient characteristics possibly associated with specific DVNC patterns, the following parameters will prospectively be assessed: the psoriasis area and severity index score (PASI), presence of nail psoriasis such as pitting, onycholysis, hyperkeratosis, discoloration, disfiguring, or hemorrhages, presence of psoriasis arthritis, demographic and clinical data (e.g. age, gender, duration of the disease, drug intake, circulating markers of endothelial damage and inflammation, accompanying medical conditions (incl. history of cardiovascular disease).

Parameter	Definition	Physiological image
<b>Capillary morphology</b>	Vascular structure	U-shaped, parallel to nail surface
<b>Capillary density</b>	Number of capillaries per linear mm	>9 -10/ linear mm
<b>Capillary loop diameter</b>	Distance between afferent and efferent loop	<20 $\mu\text{m}$
<b>Capillary enlargement</b>	> 20 $\mu\text{m}$ loop diameter	Usually absent
<b>Megacapillaries</b>	Homogeneously enlarged loops with a diameter > 50 $\mu\text{m}$	Absent
<b>Capillary blood flow</b>	Blood circulation in the capillary	Dynamic, no stasis/thrombosis
<b>Tortuosity</b>	Afferent and efferent portion cross at least two times	Usually absent
<b>Haemorrhages</b>	Extravasal detection of erythrocytes or their degradation products (Type A: point-like microbleeding, Type B: larger confluent bleeding)	Usually absent
<b>Elongation</b>	Increased length of the capillaries by 50 % or 350 $\mu\text{m}$	Usually absent
<b>Ramification</b>	Abnormal connections between afferent and efferent portion or e.g. tortuous, branching, bushy or coiled	Absent
<b>Capillary loss</b>	Multifocal (avascular areas) or diffuse loss of capillaries	Absent
<b>Pericapillary oedema</b>	Pericapillary increase in interstitial fluid	Absent

**Table 1** Parameters and morphologic findings in capillaroscopy [18,15,19,20]

### Statistical considerations

1  
2  
3 As this is a first pilot study investigating capillary pathologies by DVNC in patients with  
4 psoriasis vulgaris, a formal sample size calculation is neither applicable nor feasible. A  
5 sample size of 75 complete and evaluable datasets is sufficient to assess the potential impact  
6 of psoriasis on capillary pathologies by descriptive statistics. It is planned to investigate 50  
7 patients with psoriasis vulgaris alone or psoriasis vulgaris accompanied by psoriasis arthritis  
8 and to compare the results to 25 healthy subjects. Taking into account a dropout rate of 20%,  
9 at least 96 patients shall be recruited. All endpoints will be analyzed descriptively by  
10 tabulation of the measures of the empirical distributions. Depending on the scale level of the  
11 variables, means, standard deviations, medians, and first and third quartiles, as well as either  
12 minimum and maximum or absolute and relative frequency, will be reported. Descriptive P-  
13 values of the corresponding statistical tests comparing results of patients to healthy subjects  
14 will be given, together with the associated 95% confidence intervals. When appropriate,  
15 graphical methods will be used to visualize the findings.

### 31 **Ethical considerations and regulatory obligations**

32  
33  
34 The study is conducted in accordance with the Declaration of Helsinki principles (2013),  
35 applicable local government regulations, and independent Ethics Committee policies and  
36 procedures. Before initiation of the study, the protocol was presented and approved by the  
37 independent ethics committee of the medical faculty of the University of Heidelberg (Ethics  
38 approval number S-447/2017). There are no personal benefits and no additional risks for  
39 study participants.

### 48 **Recruitment and status of the study**

49  
50  
51 Ethical approval was granted in September 2017. Planned date of first enrollment is January  
52 2018. The estimated time required for recruitment of 96 patients is 12 months. The total  
53 duration of the study is expected to be 24 months, including statistical analysis.

## FOOTNOTES

### Funding statement

This work was supported by a grant from Novartis Pharma GmbH, Nürnberg, Germany.

### Study registration

This study was registered at the German Clinical Trial Register (DRKS): DRKS00012856 (<https://www.germanctr.de/>).

### Conflicts of interest

The authors declared that they have no competing interests.

### Authors' contribution

C. Fink, I. Bertlich, E. Hoxha, A. Enk and H.A. Haenssle participated in the development and the implementation of the study (writing of the protocol, submission to ethics committee, data management). C. Fink, I. Bertlich, E. Hoxha, A. Enk and H.A. Haenssle helped to draft and to review the paper. All authors read and approved the final manuscript.

## REFERENCES

1. Smith V, Thevissen K, Trombetta AC, et al. Nailfold capillaroscopy and clinical applications in systemic sclerosis. *Microcirculation* 2016;23:364–372.
2. Martínez-Sales V, Vila V, Ricart JM. Increased circulating endothelial cells and microparticles in patients with psoriasis. *Clin Hemorheol Microcirc*. 2015;60(3):283-90.

- 1  
2  
3 3. Hofstee HM, Vonk Noordegraaf A, Voskuyl AE, et al. Nailfold capillary density is associated with  
4 the presence and severity of pulmonary arterial hypertension in systemic sclerosis. *Ann Rheum Dis*  
5 2009;68:191–5  
6
- 7  
8  
9 4. Nast A, Boehncke WH, Mrowietz U, et al. S3 – Guidelines on the treatment of psoriasis vulgaris  
10 (English version). Update. *J Dtsch Dermatol Ges* 2012;10:S1–s95  
11
- 12  
13  
14 5. Gyldenløve M, Jensen P, Løvendorf MB et al. ‘Short-term treatment with methotrexate does not  
15 affect microvascular endothelial function in patients with psoriasis’. *J Eur Acad Dermatol Venereol*  
16 2015;29:591–594.  
17
- 18  
19  
20 6. Gonzalez-juanatey C, Llorca J, Amigo-Diaz E, et al. High prevalence of subclinical atherosclerosis  
21 in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis  
22 risk factors. *Arthritis & Rheumatism* 2007;57:1074–1080  
23
- 24  
25  
26 7. Pirro M, Stingeni L, Vaudo G et al. Systemic inflammation and imbalance between endothelial  
27 injury and repair in patients with psoriasis are associated with preclinical atherosclerosis. *Eur J Prev*  
28 *Cardiol* 2015;22(8):1027-35  
29
- 30  
31  
32 8. Barton SP, Abdullah MS, Marks R. Quantification of microvascular changes in the skin in patients  
33 with psoriasis. *Br J Dermatol* 1992;126:569±74.  
34
- 35  
36  
37 9. Espinoza LR, Vasey FB, Espinoza CG et al. Vascular changes in psoriatic synovium. A light and  
38 electron microscopic study. *Arthritis Rheum* 1982;25:677±84  
39
- 40  
41  
42 10. Redisch W, Messina EJ, Hughes G, et al. Capillaroscopic observations in rheumatic diseases. *Ann*  
43 *Rheum Dis* 1970;29:244±53  
44
- 45  
46  
47 11. Zaric D, Clemmensen OJ, Worm AM, et al. Capillary microscopy of the nail fold in patients with  
48 psoriasis and psoriatic arthritis. *Dermatologica* 1982;164:10±14  
49
- 50  
51  
52 12. Ohtsuka T, Yamakage A, Miyachi Y. Statistical definition of nailfold capillary pattern in patients  
53 with psoriasis. *Int J Dermatol* 1994;33:779±82  
54
- 55  
56  
57
- 58
- 59
- 60


- 1  
2  
3 13. Ribeiro CF Siqueira EB, Holler AP et al. Periungual capillaroscopy in psoriasis. *An Bras Dermatol*  
4 2012;87(4):550-3.  
5  
6  
7 14. Bhushan M, Moore T, Herrick AL et al. Nailfold video capillaroscopy in psoriasis. *Br J Dermatol*  
8 2000;142(6):1171-6  
9  
10  
11  
12 15. Cutolo M, editor. Atlas of capillaroscopy in rheumatic diseases. Milano: Elsevier Srl; 2010.  
13  
14  
15 16. Sander O, Sunderkötter C, Kötter I et al. Kapillarmikroskopie Durchführung und Nomenklatur. *Z*  
16 *Rheumatol* 2010;69:253–62.  
17  
18  
19 17. Smith V, Pizzorni C, De Keyser F, et al. Reliability of the qualitative and semiquantitative  
20 nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. *Annals of*  
21 *the Rheumatic Diseases* 2010;69:1092-1096.  
22  
23  
24  
25  
26 18. Klein-Weigel PF, Sunderkötter C, Sander O. Nailfold capillaroscopy microscopy - an  
27 interdisciplinary appraisal. *Vasa* 2016;45(5):353-64.  
28  
29  
30  
31 19. Jung, P, Trautinger, F. Capillaroscopy. *J Dtsch Dermatol Ges* 2013;11:731–736.  
32  
33  
34 20. Chojnowski MM, Felis-Giemza A, Olesińska M. Capillaroscopy – a role in modern rheumatology.  
35 *Reumatologia*. 2016;54(2):67-72.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## FIGURE Legend

**Figure 1** Flowchart of the study

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



190x254mm (300 x 300 DPI)

# BMJ Open

## Evaluation of capillary pathologies by nailfold capillaroscopy in patients with psoriasis vulgaris: Study protocol for a prospective, controlled, pilot study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021595.R1
Article Type:	Protocol
Date Submitted by the Author:	06-Mar-2018
Complete List of Authors:	Fink, Christine; University Hospital Heidelberg, Department of Dermatology Bertlich, Ines; University Hospital Heidelberg, Department of Dermatology Hoxha, Elti; University Hospital Heidelberg, Department of Dermatology Enk, Alexander; University Hospital Heidelberg, Department of Dermatology Haenssle, Holger; University Hospital Heidelberg, Department of Dermatology
<b>Primary Subject Heading</b>:	Dermatology
Secondary Subject Heading:	Dermatology
Keywords:	Psoriasis < DERMATOLOGY, nailfold capillaroscopy, capillary pattern, capillary morphology

SCHOLARONE™  
Manuscripts

Only



1  
2  
3 **Evaluation of capillary pathologies by nailfold capillaroscopy in patients with psoriasis**  
4 **vulgaris: Study protocol for a prospective, controlled, pilot study**  
5  
6  
7  
8  
9

10  
11 **Authors:**

12  
13 Christine Fink<sup>1</sup>, Ines Bertlich<sup>1</sup>, Elti Hoxha<sup>1</sup>, Alexander Enk<sup>1</sup>, Holger A Haenssle<sup>1</sup>  
14  
15

16  
17  
18  
19 **Departments/Institutions:**

20  
21 <sup>1</sup>Department of Dermatology, University of Heidelberg, Germany  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 **Word count:** 1697  
37  
38  
39  
40

41 **Corresponding Author:**

42 Prof. Dr. med. Holger A. Haenssle

43 Department of Dermatology, University of Heidelberg,

44 Im Neuenheimer Feld 440, 69120 Heidelberg

45 Holger.Haenssle@med.uni-heidelberg.de

46 Fon: +49-6221-56-39555

47 Fax: +49-6221-56-4996  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

### Introduction

Psoriasis vulgaris was shown to be an independent factor increasing the risk of several comorbidities such as obesity, diabetes and dyslipidemia with an increased risk of stroke and myocardial infarction. We hypothesize that early endothelial dysfunction, which plays a crucial role in the pathogenesis of atherosclerosis, may be detected by digital video nailfold capillaroscopy (DVNC) at the level of the dermal capillary microvasculature as a surrogate parameter. Nailfolds represent the only body site allowing for a non-invasive assessment of the capillary microvasculature at a horizontal plane. DVNC is a well-established diagnostic tool for in-vivo assessment of the peripheral microcirculation by evaluating the morphology of dermal papillary capillaries. To date, reports on morphological changes of the non-lesional nailfold capillaries in patients with psoriasis vulgaris are scarce and the existing data is not conclusive.

### Methods and analysis

This is a prospective, single center, non-randomized, controlled pilot study assessing the capillary patterns in 75 subjects affected by psoriasis vulgaris. Non-lesional nailfold capillaries will be imaged by means of DVNC (Optilia Digital Capillaroscopy System, Optilia Instruments AB, Sollentuna, Sweden) in 50 patients affected by psoriasis vulgaris and 25 healthy controls. Assessments will include a qualitative, descriptive analysis of the nailfold capillaries' morphology, as well as a quantitative investigation (frequency, extent) of changes in capillary patterns. Moreover, patients' characteristics associated with the manifestation of nailfold capillaries' pathologies including well-known cardiovascular risk markers will be studied.

### Ethics and dissemination

Ethical approval was provided by the ethic committee of the medical faculty of the University of Heidelberg (Ethics approval number S-447/2017). The design and the final results of the study will be published and made available to the public.

### **Study registration**

This study is registered at the German Clinical Trial Register (DRKS): DRKS00012856

### **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- This is a pilot case-control study designed to investigate the frequency and extent of morphological changes of nailfold capillaries in patients with psoriasis vulgaris in comparison to healthy controls.
- Pathological changes in nailfold capillaries of psoriasis patients and healthy controls will be statistically correlated with collected biomarkers and clinical findings indicative of cardiovascular disease.
- Statistical analyses of associations between pathological patterns of nailfold capillaries and cardiovascular disease will be performed to assess the usefulness of capillaroscopy as a surrogate parameter for determining the extent of endothelial dysfunction in psoriasis patients.
- Since this is a pilot study, limitations arise from the single-site setting and the small number of subjects in both groups.

## INTRODUCTION

Digital video nailfold capillaroscopy (DVNC) is routinely used for in-vivo assessment of the peripheral microcirculation by evaluating the morphology of dermal papillary capillaries [1]. Long before onset of clinical symptoms pathological capillary patterns may be observed in a number of systemic diseases, which are accompanied by vascular damage. Therefore, DVNC might be helpful to define surrogate parameters indicative of initial manifestation of cardiovascular disease [2]. Additionally, capillary abnormalities were shown to potentially reflect the severity and long-term prognosis of underlying diseases. For instance, in systemic sclerosis an association between a decreased capillary density and the development and the severity of pulmonary arterial hypertension was detected [3]. Psoriasis vulgaris is a common chronic skin disease which is accompanied by a number of comorbidities, that are possibly induced by a chronic, low-grade, systemic inflammation leading to vascular insufficiency and finally to clinically relevant atherosclerosis [2,4,5]. Atherosclerosis in psoriasis patients was shown to be caused by a transfer of inflammatory cells and cytokines from the skin to endothelial tissue and internal organs causing systemic inflammation [2,5,6]. Endothelial dysfunction is often used as a surrogate marker for atherosclerosis and several studies have shown impaired endothelial function in patients with moderate to severe psoriasis or psoriatic arthritis [2,6,7]. Besides broad evidence for an increased risk of large vessel atherosclerosis, previous studies also indicated changes of the microvasculature in the papillary dermis of psoriatic plaques and the synovia of psoriatic joints [8,9]. However, until today only little is known about changes in the microcirculation in non-lesional skin of psoriasis patients. The reported data are controversial with regard to pathologies of nailfold capillaries, which most probably reflects the polyetiology and polymorphology of psoriasis. In one of the earliest studies Redisch et al. revealed tortuous capillaries with tight terminal convolutions in lesional and non-lesional skin of psoriasis patients [10]. A decreased capillary density, shorter

1  
2  
3 capillaries, more nailfold hemorrhages and sluggish blood flow in patients with psoriasis  
4 arthritis were observed by Zaric et al. when compared to healthy controls [11]. A pattern with  
5 shorter and more tortuous capillaries was significantly correlated with periungual psoriatic  
6 plaques, nail pitting, onycholysis, and the extent of the involved body surface in a study by  
7 Ohtsuka et al. [12]. A study by Ribeiro et al. showed a lower capillary density, increased  
8 avascular areas and an increased number of coiled capillaries in the nailfold of patients with  
9 psoriasis [13]. Finally, Bushan et al. reported a significantly decreased capillary loop density  
10 and a reduction of arterial and venous capillary limb diameters but found no other of the  
11 previously described morphological abnormalities in any of the patients [14].

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22 The aim of our study is to gather further evidence concerning the morphology, frequency and  
23 the extent of nailfold capillary changes in patients with psoriasis vulgaris and to identify  
24 patient characteristics possibly associated with specific pathological DVNC patterns. We  
25 hypothesize that early endothelial dysfunction as caused by the systemic inflammatory  
26 immune response in psoriasis patients may be detected by DVNC at the level of the dermal  
27 capillary microvasculature.

## 28 29 30 31 32 33 34 35 36 37 **DESIGN/METHODS**

### 38 39 40 **Study design and objectives**

41  
42  
43 This is a prospective, single center, non-randomized, controlled pilot study assessing the  
44 capillary patterns in 75 individuals by means of DVNC. The primary objective of this study is  
45 to investigate the frequency, the extent, and the morphology of changes in capillary patterns  
46 in 50 patients that are either affected by psoriasis vulgaris alone (group A) or by psoriasis  
47 vulgaris in combination with accompanying psoriasis arthritis (group B) compared to 25  
48 healthy subjects (group C) (Fig. 1). A secondary objective of this study is to identify patient  
49 characteristics that are statistically associated with specific DVNC patterns (e.g. psoriasis  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 severity, nail psoriasis, age, gender, duration of the disease, manifest cardiovascular diseases  
4 and circulating markers of endothelial damage and inflammation).  
5  
6  
7

### 8 **Criteria for inclusion/exclusion**

9

10  
11 Inclusion criteria for group A and B are: patients  $\geq 18$  and  $\leq 80$  years of age with the diagnosis  
12 of chronic moderate to severe plaque psoriasis (defined as involved BSA  $\geq 10\%$  and PASI  
13 score  $\geq 10$  and DLQI  $\geq 10$ ) with or without psoriatic arthritis for at least 6 months (duration  
14 since diagnosis may be reported by the patient). Exclusion criteria for group A and B are:  
15 patients under current exposure to any anti-psoriatic or immunosuppressive systemic therapy  
16 (discontinuation for at least 4 weeks prior to DVNC is mandatory), patients with any other  
17 skin disease or therapy affecting the area of interest for DVNC and subjects with non-plaque  
18 forms or drug-induced psoriasis as well as active ongoing inflammatory diseases other than  
19 psoriasis that might confound study evaluations. Inclusion criteria for group C (healthy  
20 subjects) are: patients  $\geq 18$  and  $\leq 80$  years of age with no skin disease and no inflammatory  
21 rheumatic disease. Patients with any skin disease affecting the area of interest for DVNC or  
22 any active ongoing inflammatory diseases that might confound study evaluations will be  
23 excluded. Patients will be excluded from all three groups if any cosmetic procedure involving  
24 the nailfold area was performed over the last 4 weeks since potential micro-traumata may lead  
25 to false-positive results in DVNC [15, 16].  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

### 44 **Methods**

45

46  
47 In this study the nailfold capillaries of 75 individuals will be evaluated by DVNC (Optilia  
48 Digital Capillaroscopy System, Optilia OP-120 021, Optilia Instruments AB, Sweden) (Fig.  
49 1). DVNC will be performed with low magnification (x20; for global evaluation of the entire  
50 nailfold area) and high magnification (x200; for more detailed observations of separate  
51 capillaries). Nailfolds of the 2nd to the 5th finger of both hands will be examined. For the  
52  
53  
54  
55  
56  
57  
58  
59  
60

high magnification setting a total of 32 pictures (4 consecutive images per nailfold, each covering 1 mm) will be taken [15, 16]. For standardization and quality assurance the DVNC is performed after 15–20 min of acclimatization at room temperature in a sitting position. Smoking and caffeinated beverages should be avoided at least four hours before DVNC to avoid capillary constriction. In our study a semiquantitative image analysis based on the microangiopathy evolution score presented by Cutolo et al. will be applied [15]. The intra- and inter-rater reliability of this semiquantitative scoring-algorithm has been demonstrated [17]. Interpretation of findings will be based on criteria established by the EULAR study group [18]. Several capillaroscopic parameters will be evaluated and scored, e.g. presence of enlarged (>20 µm loop diameter) and giant capillaries (loop diameter > 50 µm), hemorrhages and/or hemosiderin deposits, capillary loss (< 9-10 capillaries per linear mm counted at the distal row of the nailfold), disorganization of the vascular array (distribution and orientation) and ramified capillaries/neoangiogenesis (tortuous, branching, bushy, coiled) (Table 1). Optionally, further morphological characteristics may be described. To evaluate patient characteristics possibly associated with specific DVNC patterns, the following parameters will prospectively be assessed: the psoriasis area and severity index score (PASI), presence of nail psoriasis such as pitting, onycholysis, hyperkeratosis, discoloration, disfiguring, or hemorrhages, presence of psoriasis arthritis, demographic and clinical data (e.g. age, gender, duration of the disease, drug intake, circulating markers of endothelial damage and inflammation, accompanying medical conditions (incl. history of cardiovascular disease).

Parameter	Definition	Physiological image
<b>Capillary morphology</b>	Vascular structure	U-shaped, parallel to nail surface
<b>Capillary density</b>	Number of capillaries per linear mm	>9 -10/ linear mm
<b>Capillary loop diameter</b>	Distance between afferent and efferent loop	<20 µm
<b>Capillary enlargement</b>	> 20 µm loop diameter	Usually absent
<b>Megacapillaries</b>	Homogeneously enlarged loops with a diameter > 50 µm	Absent
<b>Capillary blood flow</b>	Blood circulation in the capillary	Dynamic, no stasis/thrombosis
<b>Tortuosity</b>	Afferent and efferent portion cross at least two times	Usually absent
<b>Haemorrhages</b>	Extravasal detection of erythrocytes or their degradation products (Type A: point-like microbleeding, Type B: larger confluent bleeding)	Usually absent
<b>Elongation</b>	Increased length of the capillaries by 50 % or 350 µm	Usually absent

<b>Ramification</b>	Abnormal connections between afferent and efferent portion or e.g. tortuous, branching, bushy or coiled	Absent
<b>Capillary loss</b>	Multifocal (avascular areas) or diffuse loss of capillaries	Absent
<b>Pericapillary oedema</b>	Pericapillary increase in interstitial fluid	Absent

**Table 1** Parameters and morphologic findings in capillaroscopy [15,19, 20,21]

### Statistical considerations

As this is a first pilot study investigating capillary pathologies by DVNC in patients with psoriasis vulgaris, a formal sample size calculation is neither applicable nor feasible. A sample size of 75 complete and evaluable datasets is sufficient to assess the potential impact of psoriasis on capillary pathologies by descriptive statistics. It is planned to investigate 50 patients with psoriasis vulgaris alone or psoriasis vulgaris accompanied by psoriasis arthritis and to compare the results to 25 healthy subjects. Taking into account a dropout rate of 20%, at least 96 patients shall be recruited. All endpoints will be analyzed descriptively by tabulation of the measures of the empirical distributions. Depending on the scale level of the variables, means, standard deviations, medians, and first and third quartiles, as well as either minimum and maximum or absolute and relative frequency, will be reported. Descriptive P-values of the corresponding statistical tests comparing results of patients to healthy subjects will be given, together with the associated 95% confidence intervals. When appropriate, graphical methods will be used to visualize the findings.

### Ethical considerations, dissemination plan and regulatory obligations

The study is conducted in accordance with the Declaration of Helsinki principles (2013), applicable local government regulations, and independent Ethics Committee policies and procedures. Before initiation of the study, the protocol was presented and approved by the independent ethics committee of the medical faculty of the University of Heidelberg (Ethics approval number S-447/2017). The design and the final results of the study will be presented



1  
2  
3 at meetings and congresses, will be published in written form in international scientific  
4  
5 journals.  
6  
7

### 8 **Recruitment and status of the study**

9

10 Ethical approval was granted in September 2017. Planned date of first enrollment is January  
11  
12 2018. The estimated time required for recruitment of 96 patients is 12 months. The total  
13  
14 duration of the study is expected to be 24 months, including statistical analysis.  
15  
16  
17

### 18 **Patient and public involvement**

19

20  
21 Within this study 75 participants will be recruited which have no personal benefits and no  
22  
23 additional risks. However, specific pathological changes in non-invasive nailfold capillaries  
24  
25 might be identified and future patients might benefit from this study. Study results will be  
26  
27 made available to the public via press releases as launched by the media departments of the  
28  
29 authors' institutions.  
30  
31

### 32 **FOOTNOTES**

33  
34

#### 35 **Funding statement**

36

37  
38 This work was supported by a grant from Novartis Pharma GmbH, Nürnberg, Germany.  
39  
40

#### 41 **Study registration**

42

43  
44 This study was registered at the German Clinical Trial Register (DRKS): DRKS00012856  
45  
46 (<https://www.germanctr.de/>).  
47  
48

#### 49 **Conflicts of interest**

50

51  
52 The authors declared that they have no competing interests.  
53  
54

#### 55 **Authors' contribution**

56  
57  
58  
59  
60

1  
2  
3 C. Fink, I. Bertlich, E. Hoxha, A. Enk and H.A. Haenssle participated in the development and  
4 the implementation of the study (writing of the protocol, submission to ethics committee, data  
5 management). C. Fink, I. Bertlich, E. Hoxha, A. Enk and H.A. Haenssle helped to draft and to  
6 review the paper. All authors read and approved the final manuscript.  
7  
8  
9  
10

## 11 12 13 14 15 **REFERENCES**

- 16  
17  
18 1. Smith V, Thevissen K, Trombetta AC, et al. Nailfold capillaroscopy and clinical applications in  
19 systemic sclerosis. *Microcirculation* 2016;23:364–372.  
20  
21  
22 2. Martínez-Sales V, Vila V, Ricart JM. Increased circulating endothelial cells and microparticles in  
23 patients with psoriasis. *Clin Hemorheol Microcirc.* 2015;60(3):283-90.  
24  
25  
26 3. Hofstee HM, Vonk Noordegraaf A, Voskuyl AE, et al. Nailfold capillary density is associated with  
27 the presence and severity of pulmonary arterial hypertension in systemic sclerosis. *Ann Rheum Dis*  
28 2009;68:191–5  
29  
30  
31 4. Nast A, Boehncke WH, Mrowietz U, et al. S3 – Guidelines on the treatment of psoriasis vulgaris  
32 (English version). Update. *J Dtsch Dermatol Ges* 2012;10:S1–s95  
33  
34  
35 5. Gyldenløve M, Jensen P, Løvendorf MB et al. ‘Short-term treatment with methotrexate does not  
36 affect microvascular endothelial function in patients with psoriasis’. *J Eur Acad Dermatol Venereol*  
37 2015;29:591–594.  
38  
39  
40 6. Gonzalez-juanatey C, Llorca J, Amigo-Diaz E, et al. High prevalence of subclinical atherosclerosis  
41 in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis  
42 risk factors. *Arthritis & Rheumatism* 2007;57:1074–1080  
43  
44  
45 7. Pirro M, Stingeni L, Vaudo G et al. Systemic inflammation and imbalance between endothelial  
46 injury and repair in patients with psoriasis are associated with preclinical atherosclerosis. *Eur J Prev*  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 8. Barton SP, Abdullah MS, Marks R. Quantification of microvascular changes in the skin in patients  
4 with psoriasis. *Br J Dermatol* 1992;126:569±74.  
5  
6  
7 9. Espinoza LR, Vasey FB, Espinoza CG et al. Vascular changes in psoriatic synovium. A light and  
8 electron microscopic study. *Arthritis Rheum* 1982;25:677±84  
9  
10  
11  
12 10. Redisch W, Messina EJ, Hughes G, et al. Capillaroscopic observations in rheumatic diseases. *Ann*  
13 *Rheum Dis* 1970;29:244±53  
14  
15  
16  
17 11. Zaric D, Clemmensen OJ, Worm AM, et al. Capillary microscopy of the nail fold in patients with  
18 psoriasis and psoriatic arthritis. *Dermatologica* 1982;164:10±14  
19  
20  
21  
22 12. Ohtsuka T, Yamakage A, Miyachi Y. Statistical definition of nailfold capillary pattern in patients  
23 with psoriasis. *Int J Dermatol* 1994;33:779±82  
24  
25  
26  
27 13. Ribeiro CF Siqueira EB, Holler AP et al. Periungual capillaroscopy in psoriasis. *An Bras Dermatol*  
28 2012;87(4):550-3.  
29  
30  
31  
32 14. Bhushan M, Moore T, Herrick AL et al. Nailfold video capillaroscopy in psoriasis. *Br J Dermatol*  
33 2000;142(6):1171-6  
34  
35  
36  
37 15. Cutolo M, editor. Atlas of capillaroscopy in rheumatic diseases. Milano: Elsevier Srl; 2010.  
38  
39  
40  
41 16. Sander O, Sunderkötter C, Kötter I et al. Kapillarmikroskopie Durchführung und Nomenklatur. *Z*  
42 *Rheumatol* 2010;69:253–62.  
43  
44  
45  
46 17. Smith V, Pizzorni C, De Keyser F, et al. Reliability of the qualitative and semiquantitative  
47 nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. *Annals of*  
48 *the Rheumatic Diseases* 2010;69:1092-1096.  
49  
50  
51  
52 18. Smith V, Beeckman S, Herrick AL et al. An EULAR study group pilot study on reliability of  
53 simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases.  
54 *Rheumatology*, Volume 55, Issue 5, 1 May 2016, Pages 883–890  
55  
56  
57  
58  
59

1  
2  
3 19. Klein-Weigel PF, Sunderkötter C, Sander O. Nailfold capillaroscopy microscopy - an  
4 interdisciplinary appraisal. *Vasa* 2016;45(5):353-64.  
5

6  
7 20. Jung, P, Trautinger, F. Capillaroscopy. *J Dtsch Dermatol Ges* 2013;11:731–736.  
8


9  
10 21. Chojnowski MM, Felis-Giemza A, Olesińska M. Capillaroscopy – a role in modern rheumatology.  
11  
12 *Reumatologia*. 2016;54(2):67-72.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**FIGURE Legend**

**Figure 1** Flowchart of the study

For peer review only



190x254mm (300 x 300 DPI)

# BMJ Open

## Evaluation of capillary pathologies by nailfold capillaroscopy in patients with psoriasis vulgaris: Study protocol for a prospective, controlled exploratory study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021595.R2
Article Type:	Protocol
Date Submitted by the Author:	14-May-2018
Complete List of Authors:	Fink, Christine; University Hospital Heidelberg, Department of Dermatology Kilian, Samuel; Institute of Medical Biometry and Informatics, University of Heidelberg Bertlich, Ines; University Hospital Heidelberg, Department of Dermatology Hoxha, Elti; University Hospital Heidelberg, Department of Dermatology Enk, Alexander; University Hospital Heidelberg, Department of Dermatology Haenssle, Holger; University Hospital Heidelberg, Department of Dermatology
<b>Primary Subject Heading</b>:	Dermatology
Secondary Subject Heading:	Dermatology
Keywords:	Psoriasis < DERMATOLOGY, nailfold capillaroscopy, capillary pattern, capillary morphology

SCHOLARONE™  
Manuscripts

1  
2  
3 **Evaluation of capillary pathologies by nailfold capillaroscopy in patients with psoriasis**  
4 **vulgaris: Study protocol for a prospective, controlled exploratory study**  
5  
6  
7  
8  
9  
10

11 **Authors:**

12 Christine Fink<sup>1</sup>, Samuel Kilian<sup>2</sup>, Ines Bertlich<sup>1</sup>, Elti Hoxha<sup>1</sup>, Alexander Enk<sup>1</sup>, Holger A  
13 Haenssle<sup>1</sup>  
14  
15  
16  
17  
18  
19  
20

21 **Departments/Institutions:**

22 <sup>1</sup>Department of Dermatology, University of Heidelberg, Germany  
23  
24

25 <sup>2</sup>Institute of Medical Biometry and Informatics, University of Heidelberg, Germany  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 **Word count:** 1892  
44

45 **Corresponding Author:**

46 Prof. Dr. med. Holger A. Haenssle

47 Department of Dermatology, University of Heidelberg,

48 Im Neuenheimer Feld 440, 69120 Heidelberg

49 Holger.Haenssle@med.uni-heidelberg.de

50 Fon: +49-6221-56-39555

51 Fax: +49-6221-56-4996  
52  
53  
54  
55  
56  
57  
58  
59  
60



## ABSTRACT

### Introduction

Psoriasis vulgaris was shown to be an independent factor increasing the risk of several comorbidities such as obesity, diabetes and dyslipidemia with an increased risk of stroke and myocardial infarction. We hypothesize that early endothelial dysfunction, which plays a crucial role in the pathogenesis of atherosclerosis, may be detected by digital video nailfold capillaroscopy (DVNC) at the level of the dermal capillary microvasculature as a surrogate parameter. Nailfolds represent the only body site allowing for a non-invasive assessment of the capillary microvasculature at a horizontal plane. DVNC is a well-established diagnostic tool for in-vivo assessment of the peripheral microcirculation by evaluating the morphology of dermal papillary capillaries. To date, reports on morphological changes of the non-lesional nailfold capillaries in patients with psoriasis vulgaris are scarce and the existing data is not conclusive.

### Methods and analysis

This is a prospective, single center, non-randomized, controlled, exploratory study assessing the capillary patterns in 100 subjects affected by psoriasis vulgaris. Non-lesional nailfold capillaries will be imaged by means of DVNC (Optilia Digital Capillaroscopy System, Optilia Instruments AB, Sollentuna, Sweden) in 50 patients affected by psoriasis vulgaris and 50 healthy controls. Assessments will include a qualitative, descriptive analysis of the nailfold capillaries' morphology, as well as a quantitative investigation (frequency, extent) of changes in capillary patterns. Moreover, patients' characteristics associated with the manifestation of nailfold capillaries' pathologies including well-known cardiovascular risk markers will be studied.

### Ethics and dissemination

Ethical approval was provided by the ethic committee of the medical faculty of the University of Heidelberg (Ethics approval number S-447/2017). The design and the final results of the study will be published and made available to the public.

### Study registration

This study is registered at the German Clinical Trial Register (DRKS): DRKS00012856

### STRENGTHS AND LIMITATIONS OF THIS STUDY

- Until today, there are only very few prospective, controlled studies investigating the frequency and extent of morphological changes of nailfold capillaries in patients with psoriasis vulgaris.
- Within this study, several patient characteristics that are associated with specific capillaroscopy patterns will be investigated in a prospective controlled setting in an unprecedented scale.
- Since this is an exploratory study, limitations arise from the small number of subjects in both groups and the non-feasibility of a formal sample size calculation due to the absence of a-priori knowledge.

### INTRODUCTION

Digital video nailfold capillaroscopy (DVNC) is routinely used for in-vivo assessment of the peripheral microcirculation by evaluating the morphology of dermal papillary capillaries [1]. Long before onset of clinical symptoms pathological capillary patterns may be observed in a number of systemic diseases, which are accompanied by vascular damage. Therefore, DVNC might be helpful to define surrogate parameters indicative of initial manifestation of cardiovascular disease [2]. Additionally, capillary abnormalities were shown to potentially

1  
2  
3 reflect the severity and long-term prognosis of underlying diseases. For instance, in systemic  
4 sclerosis an association between a decreased capillary density and the development and the  
5 severity of pulmonary arterial hypertension was detected [3]. Psoriasis vulgaris is a common  
6 chronic skin disease which is accompanied by a number of comorbidities, that are possibly  
7 induced by a chronic, low-grade, systemic inflammation leading to vascular insufficiency and  
8 finally to clinically relevant atherosclerosis [2,4,5]. Atherosclerosis in psoriasis patients was  
9 shown to be caused by a transfer of inflammatory cells and cytokines from the skin to  
10 endothelial tissue and internal organs causing systemic inflammation [2,5,6]. Endothelial  
11 dysfunction is often used as a surrogate marker for atherosclerosis and several studies have  
12 shown impaired endothelial function in patients with moderate to severe psoriasis or psoriatic  
13 arthritis [2,6,7]. Besides broad evidence for an increased risk of large vessel atherosclerosis,  
14 previous studies also indicated changes of the microvasculature in the papillary dermis of  
15 psoriatic plaques and the synovia of psoriatic joints [8,9]. However, until today only little is  
16 known about changes in the microcirculation in non-lesional skin of psoriasis patients. The  
17 reported data are controversial with regard to pathologies of nailfold capillaries, which most  
18 probably reflects the polyetiology and polymorphology of psoriasis. In one of the earliest  
19 studies Redisch et al. revealed tortuous capillaries with tight terminal convolutions in lesional  
20 and non-lesional skin of psoriasis patients [10]. A decreased capillary density, shorter  
21 capillaries, more nailfold hemorrhages and sluggish blood flow in patients with psoriasis  
22 arthritis were observed by Zaric et al. when compared to healthy controls [11]. A pattern with  
23 shorter and more tortuous capillaries was significantly correlated with periungual psoriatic  
24 plaques, nail pitting, onycholysis, and the extent of the involved body surface in a study by  
25 Ohtsuka et al. [12]. A study by Ribeiro et al. showed a lower capillary density, increased  
26 avascular areas and an increased number of coiled capillaries in the nailfold of patients with  
27 psoriasis [13]. Finally, Bushan et al. reported a significantly decreased capillary loop density  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 and a reduction of arterial and venous capillary limb diameters but found no other of the  
4  
5 previously described morphological abnormalities in any of the patients [14].  
6

7 The aim of our exploratory study is to generate hypotheses concerning the morphology,  
8  
9 frequency and the extent of nailfold capillary changes in patients with psoriasis vulgaris and  
10  
11 to identify patient characteristics possibly associated with specific pathological DVNC  
12  
13 patterns. We hypothesize that early endothelial dysfunction as caused by the systemic  
14  
15 inflammatory immune response in psoriasis patients may be detected by DVNC at the level of  
16  
17 the dermal capillary microvasculature. In addition, this exploratory study will provide the  
18  
19 necessary prerequisites for a full-scale study with a formal sample size calculation since there  
20  
21 is only little a-priori knowledge.  
22  
23  
24  
25

## 26 **DESIGN/METHODS**

### 27 **Study design and objectives**

28  
29  
30 This is a prospective, single center, non-randomized, controlled exploratory study assessing  
31  
32 the capillary patterns in 100 individuals by means of DVNC. The primary objective of this  
33  
34 study is to generate hypotheses regarding the frequency, the extent, and the morphology of  
35  
36 changes in capillary patterns in 50 patients that are either affected by psoriasis vulgaris alone  
37  
38 (group A) or by psoriasis vulgaris in combination with accompanying psoriasis arthritis  
39  
40 (group B) compared to 50 healthy subjects (group C) (Fig. 1). A secondary objective of this  
41  
42 study is to identify patient characteristics that are statistically associated with specific DVNC  
43  
44 patterns (e.g. psoriasis severity, nail psoriasis, age, gender, duration of the disease, manifest  
45  
46 cardiovascular diseases and circulating markers of endothelial damage and inflammation).  
47  
48  
49  
50  
51

### 52 **Criteria for inclusion/exclusion**

53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Inclusion criteria for group A and B are: patients  $\geq 18$  and  $\leq 80$  years of age with the diagnosis  
4 of chronic moderate to severe plaque psoriasis (defined as involved BSA  $\geq 10\%$  and PASI  
5 score  $\geq 10$  and DLQI  $\geq 10$ ) with or without psoriatic arthritis for at least 6 months (duration  
6 since diagnosis may be reported by the patient). Exclusion criteria for group A and B are:  
7 patients under current exposure to any anti-psoriatic or immunosuppressive systemic therapy  
8 (discontinuation for at least 4 weeks prior to DVNC is mandatory), patients with any other  
9 skin disease or therapy affecting the area of interest for DVNC and subjects with non-plaque  
10 forms or drug-induced psoriasis as well as active ongoing inflammatory diseases other than  
11 psoriasis that might confound study evaluations. Inclusion criteria for group C (healthy  
12 subjects) are: patients  $\geq 18$  and  $\leq 80$  years of age with no skin disease and no inflammatory  
13 rheumatic disease. Patients with any skin disease affecting the area of interest for DVNC or  
14 any active ongoing inflammatory diseases that might confound study evaluations will be  
15 excluded. Patients will be excluded from all three groups if any cosmetic procedure involving  
16 the nailfold area was performed over the last 4 weeks since potential micro-traumata may lead  
17 to false-positive results in DVNC [15, 16].  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

## 36 **Methods**

37  
38  
39 In this study the nailfold capillaries of 100 individuals will be evaluated by DVNC (Optilia  
40 Digital Capillaroscopy System, Optilia OP-120 021, Optilia Instruments AB, Sweden) (Fig.  
41 1). DVNC will be performed with low magnification (x20; for global evaluation of the entire  
42 nailfold area) and high magnification (x200; for more detailed observations of separate  
43 capillaries). Nailfolds of the 2nd to the 5th finger of both hands will be examined. For the  
44 high magnification setting a total of 32 pictures (4 consecutive images per nailfold, each  
45 covering 1 mm) will be taken [15, 16]. For standardization and quality assurance the DVNC is  
46 performed after 15–20 min of acclimatization at room temperature in a sitting position.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60 Smoking and caffeinated beverages should be avoided at least four hours before DVNC to

avoid capillary constriction. In our study a semiquantitative image analysis based on the microangiopathy evolution score presented by Cutolo et al. will be applied [15]. The intra- and inter-rater reliability of this semiquantitative scoring-algorithm has been demonstrated [17]. Interpretation of findings will be based on criteria established by the EULAR study group [18]. Several capillaroscopic parameters will be evaluated and scored, e.g. presence of enlarged (>20 µm loop diameter) and giant capillaries (loop diameter > 50 µm), hemorrhages and/or hemosiderin deposits, capillary loss (< 9-10 capillaries per linear mm counted at the distal row of the nailfold), disorganization of the vascular array (distribution and orientation) and ramified capillaries/neoangiogenesis (tortuous, branching, bushy, coiled) (Table 1). Optionally, further morphological characteristics may be described. To evaluate patient characteristics possibly associated with specific DVNC patterns, the following parameters will prospectively be assessed: the psoriasis area and severity index score (PASI), presence of nail psoriasis such as pitting, onycholysis, hyperkeratosis, discoloration, disfiguring, or hemorrhages, presence of psoriasis arthritis, demographic and clinical data (e.g. age, gender, duration of the disease, drug intake, circulating markers of endothelial damage and inflammation, accompanying medical conditions (incl. history of cardiovascular disease).

Parameter	Definition	Physiological image
<b>Capillary morphology</b>	Vascular structure	U-shaped, parallel to nail surface
<b>Capillary density</b>	Number of capillaries per linear mm	>9 -10/ linear mm
<b>Capillary loop diameter</b>	Distance between afferent and efferent loop	<20 µm
<b>Capillary enlargement</b>	> 20 µm loop diameter	Usually absent
<b>Megacapillaries</b>	Homogeneously enlarged loops with a diameter > 50 µm	Absent
<b>Capillary blood flow</b>	Blood circulation in the capillary	Dynamic, no stasis/thrombosis
<b>Tortuosity</b>	Afferent and efferent portion cross at least two times	Usually absent
<b>Haemorrhages</b>	Extravasal detection of erythrocytes or their degradation products (Type A: point-like microbleeding, Type B: larger confluent bleeding)	Usually absent
<b>Elongation</b>	Increased length of the capillaries by 50 % or 350 µm	Usually absent
<b>Ramification</b>	Abnormal connections between afferent and efferent portion or e.g. tortuous, branching, bushy or coiled	Absent
<b>Capillary loss</b>	Multifocal (avascular areas) or diffuse loss of capillaries	Absent
<b>Pericapillary oedema</b>	Pericapillary increase in interstitial fluid	Absent

**Table 1** Parameters and morphologic findings in capillaroscopy [15,19, 20,21]

## Statistical considerations

1  
2  
3 This is a first exploratory study investigating capillary pathologies by DVNC in patients with  
4 psoriasis vulgaris since there is only little a-priori knowledge about the frequency and extent  
5 of morphological changes of nailfold capillaries in patients with psoriasis vulgaris. Thus, a  
6 formal sample size calculation is not possible. This exploratory study will provide the  
7 necessary prerequisites for a formal sample size calculation for a full-scale study.  
8  
9

10  
11  
12  
13  
14 A total of 100 complete and evaluable datasets will allow obtaining a first impression of the  
15 potential impact of psoriasis on capillary pathologies by descriptive statistics. It is planned to  
16 investigate 50 patients with psoriasis vulgaris alone or psoriasis vulgaris accompanied by  
17 psoriasis arthritis and to compare the results to 50 healthy subjects. The resulting group  
18 allocation is sufficient to determine an effect size of 0.7 (Cohen's d) with a t test at 5%  
19 significance level and 80% power. Taking into account a dropout rate of 20%, at least 125  
20 patients shall be recruited. All endpoints will be analyzed descriptively by tabulation of the  
21 measures of the empirical distributions. Depending on the scale level of the variables, means,  
22 standard deviations, medians, and first and third quartiles, as well as either minimum and  
23 maximum or absolute and relative frequency, will be reported. Descriptive P-values of the  
24 corresponding statistical tests comparing results of patients to healthy subjects will be given,  
25 together with the associated 95% confidence intervals. When appropriate, graphical methods  
26 will be used to visualize the findings.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 **Ethical considerations, dissemination plan and regulatory obligations**

44  
45  
46 The study is conducted in accordance with the Declaration of Helsinki principles (2013),  
47 applicable local government regulations, and independent Ethics Committee policies and  
48 procedures. Before initiation of the study, the protocol was presented and approved by the  
49 independent ethics committee of the medical faculty of the University of Heidelberg (Ethics  
50 approval number S-447/2017). The design and the final results of the study will be presented  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 at meetings and congresses, will be published in written form in international scientific  
4  
5 journals.  
6  
7

### 8 **Recruitment and status of the study**

9

10 Ethical approval was granted in September 2017. Planned date of first enrollment is January  
11  
12 2018. The estimated time required for recruitment of 96 patients is 12 months. The total  
13  
14 duration of the study is expected to be 24 months, including statistical analysis.  
15  
16

### 17 **Patient and public involvement**

18

19 Within this study 100 participants will be recruited which have no personal benefits and no  
20  
21 additional risks. However, specific pathological changes in non-invasive nailfold capillaries  
22  
23 might be identified and future patients might benefit from this study. Study results will be  
24  
25 made available to the public via press releases as launched by the media departments of the  
26  
27 authors' institutions.  
28  
29  
30  
31

### 32 **FOOTNOTES**

33  
34

#### 35 **Funding statement**

36

37  
38 This work was supported by a grant from Novartis Pharma GmbH, Nürnberg, Germany.  
39  
40

#### 41 **Study registration**

42

43  
44 This study was registered at the German Clinical Trial Register (DRKS): DRKS00012856  
45  
46 (<https://www.germanctr.de/>).  
47  
48

#### 49 **Conflicts of interest**

50

51  
52 The authors declared that they have no competing interests.  
53  
54

#### 55 **Authors' contribution**

56  
57  
58  
59  
60



1  
2  
3 C. Fink, S. Kilian, I. Bertlich, E. Hoxha, A. Enk and H.A. Haenssle participated in the  
4 development and the implementation of the study (writing of the protocol, submission to  
5 ethics committee, data management). C. Fink, S. Kilian, I. Bertlich, E. Hoxha, A. Enk and  
6  
7 H.A. Haenssle helped to draft and to review the paper. All authors read and approved the final  
8  
9 manuscript.  
10  
11  
12  
13  
14  
15  
16

## 17 REFERENCES

- 18  
19  
20 1. Smith V, Thevissen K, Trombetta AC, et al. Nailfold capillaroscopy and clinical applications in  
21 systemic sclerosis. *Microcirculation* 2016;23:364–372.  
22  
23
- 24  
25 2. Martínez-Sales V, Vila V, Ricart JM. Increased circulating endothelial cells and microparticles in  
26 patients with psoriasis. *Clin Hemorheol Microcirc.* 2015;60(3):283-90.  
27  
28
- 29  
30 3. Hofstee HM, Vonk Noordegraaf A, Voskuyl AE, et al. Nailfold capillary density is associated with  
31 the presence and severity of pulmonary arterial hypertension in systemic sclerosis. *Ann Rheum Dis*  
32 2009;68:191–5  
33  
34
- 35  
36 4. Nast A, Boehncke WH, Mrowietz U, et al. S3 – Guidelines on the treatment of psoriasis vulgaris  
37 (English version). Update. *J Dtsch Dermatol Ges* 2012;10:S1–s95  
38  
39
- 40  
41 5. Gyldenløve M, Jensen P, Løvendorf MB et al. ‘Short-term treatment with methotrexate does not  
42 affect microvascular endothelial function in patients with psoriasis’. *J Eur Acad Dermatol Venereol*  
43 2015;29:591–594.  
44  
45
- 46  
47 6. Gonzalez-juanatey C, Llorca J, Amigo-Diaz E, et al. High prevalence of subclinical atherosclerosis  
48 in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis  
49 risk factors. *Arthritis & Rheumatism* 2007;57:1074–1080  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

- 1  
2  
3 7. Pirro M, Stingeni L, Vaudo G et al. Systemic inflammation and imbalance between endothelial  
4 injury and repair in patients with psoriasis are associated with preclinical atherosclerosis. *Eur J Prev*  
5 *Cardiol* 2015;22(8):1027-35  
6  
7  
8  
9 8. Barton SP, Abdullah MS, Marks R. Quantification of microvascular changes in the skin in patients  
10 with psoriasis. *Br J Dermatol* 1992;126:569±74.  
11  
12  
13  
14 9. Espinoza LR, Vasey FB, Espinoza CG et al. Vascular changes in psoriatic synovium. A light and  
15 electron microscopic study. *Arthritis Rheum* 1982;25:677±84  
16  
17  
18  
19 10. Redisch W, Messina EJ, Hughes G, et al. Capillaroscopic observations in rheumatic diseases. *Ann*  
20 *Rheum Dis* 1970;29:244±53  
21  
22  
23  
24 11. Zaric D, Clemmensen OJ, Worm AM, et al. Capillary microscopy of the nail fold in patients with  
25 psoriasis and psoriatic arthritis. *Dermatologica* 1982;164:10±14  
26  
27  
28  
29 12. Ohtsuka T, Yamakage A, Miyachi Y. Statistical definition of nailfold capillary pattern in patients  
30 with psoriasis. *Int J Dermatol* 1994;33:779±82  
31  
32  
33  
34 13. Ribeiro CF Siqueira EB, Holler AP et al. Periungual capillaroscopy in psoriasis. *An Bras Dermatol*  
35 2012;87(4):550-3.  
36  
37  
38 14. Bhushan M, Moore T, Herrick AL et al. Nailfold video capillaroscopy in psoriasis. *Br J Dermatol*  
39 2000;142(6):1171-6  
40  
41  
42  
43 15. Cutolo M, editor. Atlas of capillaroscopy in rheumatic diseases. Milano: Elsevier Srl; 2010.  
44  
45  
46 16. Sander O, Sunderkötter C, Kötter I et al. Kapillarmikroskopie Durchführung und Nomenklatur. *Z*  
47 *Rheumatol* 2010;69:253–62.  
48  
49  
50 17. Smith V, Pizzorni C, De Keyser F, et al. Reliability of the qualitative and semiquantitative  
51 nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. *Annals of*  
52 *the Rheumatic Diseases* 2010;69:1092-1096.  
53  
54  
55  
56  
57  
58  
59


- 1  
2  
3 18. Smith V, Beeckman S, Herrick AL et al. An EULAR study group pilot study on reliability of  
4 simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases.  
5 Rheumatology, Volume 55, Issue 5, 1 May 2016, Pages 883–890  
6  
7  
8  
9 19. Klein-Weigel PF, Sunderkötter C, Sander O. Nailfold capillaroscopy microscopy - an  
10 interdisciplinary appraisal. *Vasa* 2016;45(5):353-64.  
11  
12  
13  
14 20. Jung, P, Trautinger, F. Capillaroscopy. *J Dtsch Dermatol Ges* 2013;11:731–736.  
15  
16  
17 21. Chojnowski MM, Felis-Giemza A, Olesińska M. Capillaroscopy – a role in modern rheumatology.  
18 *Reumatologia*. 2016;54(2):67-72.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**FIGURE Legend**

**Figure 1** Flowchart of the study

For peer review only



190x254mm (300 x 300 DPI)

# BMJ Open

## Evaluation of capillary pathologies by nailfold capillaroscopy in patients with psoriasis vulgaris: Study protocol for a prospective, controlled exploratory study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021595.R3
Article Type:	Protocol
Date Submitted by the Author:	12-Jul-2018
Complete List of Authors:	Fink, Christine; University Hospital Heidelberg, Department of Dermatology Kilian, Samuel; Institute of Medical Biometry and Informatics, University of Heidelberg Bertlich, Ines; University Hospital Heidelberg, Department of Dermatology Hoxha, Elti; University Hospital Heidelberg, Department of Dermatology Bardehle, Felicitas; University Hospital Heidelberg, Department of Dermatology Enk, Alexander; University Hospital Heidelberg, Department of Dermatology Haenssle, Holger; University Hospital Heidelberg, Department of Dermatology
<b>Primary Subject Heading</b>:	Dermatology
Secondary Subject Heading:	Dermatology
Keywords:	Psoriasis < DERMATOLOGY, nailfold capillaroscopy, capillary pattern, capillary morphology

SCHOLARONE™  
Manuscripts

1  
2  
3 **Evaluation of capillary pathologies by nailfold capillaroscopy in patients with psoriasis**  
4 **vulgaris: Study protocol for a prospective, controlled exploratory study**  
5  
6  
7  
8  
9  
10

11 **Authors:**

12 Christine Fink<sup>1</sup>, Samuel Kilian<sup>2</sup>, Ines Bertlich<sup>1</sup>, Elti Hoxha<sup>1</sup>, Felicitas Bardehle<sup>1</sup>, Alexander  
13 Enk<sup>1</sup>, Holger A Haenssle<sup>1</sup>  
14  
15  
16  
17  
18  
19  
20

21 **Departments/Institutions:**

22 <sup>1</sup>Department of Dermatology, University of Heidelberg, Germany  
23  
24

25 <sup>2</sup>Institute of Medical Biometry and Informatics, University of Heidelberg, Germany  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 **Word count:** 1942  
44

45 **Corresponding Author:**

46 Prof. Dr. med. Holger A. Haenssle

47 Department of Dermatology, University of Heidelberg,

48 Im Neuenheimer Feld 440, 69120 Heidelberg

49 Holger.Haenssle@med.uni-heidelberg.de

50 Fon: +49-6221-56-39555

51 Fax: +49-6221-56-4996  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

### Introduction

Psoriasis vulgaris was shown to be an independent factor increasing the risk of several comorbidities such as obesity, diabetes and dyslipidemia with an increased risk of stroke and myocardial infarction. We hypothesize that early endothelial dysfunction, which plays a crucial role in the pathogenesis of atherosclerosis, may be detected by digital video nailfold capillaroscopy (DVNC) at the level of the dermal capillary microvasculature as a surrogate parameter. Nailfolds represent the only body site allowing for a non-invasive assessment of the capillary microvasculature at a horizontal plane. DVNC is a well-established diagnostic tool for in-vivo assessment of the peripheral microcirculation by evaluating the morphology of dermal papillary capillaries. To date, reports on morphological changes of the non-lesional nailfold capillaries in patients with psoriasis vulgaris are scarce and the existing data is not conclusive.

### Methods and analysis

This is a prospective, single center, non-randomized, controlled, exploratory study assessing the capillary patterns in 100 subjects affected by psoriasis vulgaris. Non-lesional nailfold capillaries will be imaged by means of DVNC (Optilia Digital Capillaroscopy System, Optilia Instruments AB, Sollentuna, Sweden) in 50 patients affected by psoriasis vulgaris and 50 healthy controls. Assessments will include a qualitative, descriptive analysis of the nailfold capillaries' morphology, as well as a quantitative investigation (frequency, extent) of changes in capillary patterns. Moreover, patients' characteristics associated with the manifestation of nailfold capillaries' pathologies including well-known cardiovascular risk markers will be studied.

### Ethics and dissemination



Ethical approval was provided by the ethic committee of the medical faculty of the University of Heidelberg (Ethics approval number S-447/2017). The design and the final results of the study will be published and made available to the public.

### Study registration

This study is registered at the German Clinical Trial Register (DRKS): DRKS00012856

### STRENGTHS AND LIMITATIONS OF THIS STUDY

- Until today, there are only very few prospective, controlled studies investigating the frequency and extent of morphological changes of nailfold capillaries in patients with psoriasis vulgaris.
- Within this study, several patient characteristics and their associated specific capillaroscopy patterns will be investigated in a prospective controlled setting on an unprecedented scale.
- Since this is an exploratory study, limitations arise from the small number of subjects in both groups. Moreover, a formal sample size calculation is not feasible due to the absence of a-priori knowledge.

### INTRODUCTION

Digital video nailfold capillaroscopy (DVNC) is routinely used for in-vivo assessment of the peripheral microcirculation by evaluating the morphology of dermal papillary capillaries [1]. Long before onset of clinical symptoms pathological capillary patterns may be observed in a number of systemic diseases, which are accompanied by vascular damage. Therefore, DVNC might be helpful to define surrogate parameters indicative of initial manifestation of cardiovascular disease [2]. Additionally, capillary abnormalities were shown to potentially

1  
2  
3 reflect the severity and long-term prognosis of underlying diseases. For instance, in systemic  
4 sclerosis an association between a decreased capillary density and the development and the  
5 severity of pulmonary arterial hypertension was detected [3].  
6  
7

8  
9 Psoriasis vulgaris is a common chronic skin disease which is accompanied by a number of  
10 comorbidities that are possibly induced by a chronic, low-grade, systemic inflammation  
11 leading to vascular insufficiency and finally to clinically relevant atherosclerosis [2,4,5].  
12  
13

14 Atherosclerosis in psoriasis patients was shown to be caused by a transfer of inflammatory  
15 cells and cytokines from the skin to endothelial tissue and internal organs causing systemic  
16 inflammation [2,5,6]. Endothelial dysfunction is often used as a surrogate marker for  
17 atherosclerosis and several studies have shown impaired endothelial function in patients with  
18 moderate to severe psoriasis or psoriatic arthritis [2,6,7]. Besides broad evidence for an  
19 increased risk of large vessel atherosclerosis, previous studies also indicated changes of the  
20 microvasculature in the papillary dermis of psoriatic plaques and the synovia of psoriatic  
21 joints [8,9]. However, until today only little is known about changes in the microcirculation in  
22 non-lesional skin of psoriasis patients. The reported data is controversial with regard to  
23 pathologies of nailfold capillaries, which most probably reflects the polyetiology and  
24 polymorphology of psoriasis. In one of the earliest studies Redisch et al. revealed tortuous  
25 capillaries with tight terminal convolutions in lesional and non-lesional skin of psoriasis  
26 patients [10]. A decreased capillary density, shorter capillaries, more nailfold hemorrhages  
27 and sluggish blood flow in patients with psoriasis arthritis were observed by Zaric et al. when  
28 compared to healthy controls [11]. A pattern with shorter and more tortuous capillaries was  
29 significantly correlated with periungual psoriatic plaques, nail pitting, onycholysis, and the  
30 extent of the involved body surface in a study by Ohtsuka et al. [12]. A study by Ribeiro et al.  
31 showed a lower capillary density, increased avascular areas and an increased number of coiled  
32 capillaries in the nailfold of patients with psoriasis [13]. Finally, Bushan et al. reported a  
33 significantly decreased capillary loop density and a reduction of arterial and venous capillary  
34

35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100

101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160

161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200

201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260

261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300

limb diameters but found no other of the previously described morphological abnormalities in any of the patients [14].

The aim of our exploratory study is to generate hypotheses concerning the morphology, frequency and the extent of nailfold capillary changes in patients with psoriasis vulgaris and to identify patient characteristics possibly associated with specific pathological DVNC patterns. We hypothesize that early endothelial dysfunction as caused by the systemic inflammatory immune response in psoriasis patients may be detected by DVNC at the level of the dermal capillary microvasculature. In addition, this exploratory study will provide the necessary prerequisites for a full-scale study with a formal sample size calculation since there is only little a-priori knowledge.

## DESIGN/METHODS

### Study design and objectives

This is a prospective, single center, non-randomized, controlled exploratory study assessing the capillary patterns in 100 individuals by means of DVNC. The primary objective of this study is to generate hypotheses regarding the frequency, the extent, and the morphology of capillary patterns in non-lesional skin of 50 patients that are either affected by psoriasis vulgaris alone (group A) or by psoriasis vulgaris in combination with accompanying psoriasis arthritis (group B) compared to 50 healthy subjects (group C) (Fig. 1). A secondary objective of this study is to identify patient characteristics that are statistically associated with specific DVNC patterns (e.g. psoriasis severity, nail psoriasis, age, gender, duration of the disease, manifest cardiovascular diseases and circulating markers of endothelial damage and inflammation).

### Criteria for inclusion/exclusion

1  
2  
3 Inclusion criteria for group A and B are: patients  $\geq 18$  and  $\leq 80$  years of age with the diagnosis  
4 of chronic moderate to severe plaque psoriasis (defined as involved BSA  $\geq 10\%$  and/or PASI  
5 score  $\geq 10$  and DLQI  $\geq 10$ ) with or without psoriatic arthritis for at least 6 months (duration  
6 since diagnosis may be reported by the patient). Exclusion criteria for group A and B are:  
7 patients under current exposure to any anti-psoriatic or immunosuppressive systemic therapy  
8 (discontinuation for at least 4 weeks prior to DVNC is mandatory), patients with any other  
9 skin disease or therapy affecting the area of interest for DVNC and subjects with non-plaque  
10 forms or drug-induced psoriasis as well as active ongoing inflammatory diseases other than  
11 psoriasis that might confound study evaluations. Inclusion criteria for group C (healthy  
12 subjects) are: patients  $\geq 18$  and  $\leq 80$  years of age with no skin disease and no inflammatory  
13 rheumatic or cardiovascular disease. Patients with any skin disease affecting the area of  
14 interest for DVNC or any active ongoing inflammatory disease that might confound study  
15 evaluations will be excluded. Patients will be excluded from all three groups if any cosmetic  
16 procedure involving the nailfold area was performed over the last 4 weeks since potential  
17 micro-traumata may lead to false-positive results in DVNC [15, 16].  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

## 36 **Methods**

37  
38  
39 In this study the nailfold capillaries of 100 individuals will be evaluated by DVNC (Optilia  
40 Digital Capillaroscopy System, Optilia OP-120 021, Optilia Instruments AB, Sweden) (Fig.  
41 1). DVNC will be performed with low magnification (x20; for global evaluation of the entire  
42 nailfold area) and high magnification (x200; for more detailed observation of separate  
43 capillaries). Nailfolds of the 2nd to the 5th finger of both hands will be examined. For the  
44 high magnification setting a total of 32 pictures (4 consecutive images per nailfold, each  
45 covering 1 mm) will be taken [15, 16]. For standardization and quality assurance the DVNC is  
46 performed after 15–20 min of acclimatization at room temperature in a sitting position.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60 Smoking and caffeinated beverages should be avoided at least four hours before DVNC to

avoid capillary constriction. In our study a semiquantitative image analysis based on the microangiopathy evolution score presented by Cutolo et al. will be applied [15]. The intra- and inter-rater reliability of this semiquantitative scoring-algorithm has been demonstrated [17]. Interpretation of findings will be based on criteria established by the EULAR study group [18]. Several capillaroscopic parameters will be evaluated and scored, e.g. presence of enlarged (>20  $\mu\text{m}$  loop diameter) and giant capillaries (loop diameter > 50  $\mu\text{m}$ ), hemorrhages and/or hemosiderin deposits, capillary loss (< 9-10 capillaries per linear mm counted at the distal row of the nailfold), disorganization of the vascular array (distribution and orientation) and ramified capillaries/neoangiogenesis (tortuous, branching, bushy, coiled) (Table 1). Optionally, further morphological characteristics may be described. To evaluate patient characteristics possibly associated with specific DVNC patterns, the following parameters will prospectively be assessed: the psoriasis area and severity index score (PASI), presence of nail psoriasis such as pitting, onycholysis, hyperkeratosis, discoloration, disfiguring, or hemorrhages, presence of psoriasis arthritis, demographic and clinical data (e.g. age, gender, duration of the disease, drug intake, circulating markers of endothelial damage and inflammation (Table 2), accompanying medical conditions (incl. history of cardiovascular disease).

Parameter	Definition	Physiological image
<b>Capillary morphology</b>	Vascular structure	U-shaped, parallel to nail surface
<b>Capillary density</b>	Number of capillaries per linear mm	>9 -10/ linear mm
<b>Capillary loop diameter</b>	Distance between afferent and efferent loop	<20 $\mu\text{m}$
<b>Capillary enlargement</b>	> 20 $\mu\text{m}$ loop diameter	Usually absent
<b>Megacapillaries</b>	Homogeneously enlarged loops with a diameter > 50 $\mu\text{m}$	Absent
<b>Capillary blood flow</b>	Blood circulation in the capillary	Dynamic, no stasis/thrombosis
<b>Tortuosity</b>	Afferent and efferent portion cross at least two times	Usually absent
<b>Haemorrhages</b>	Extravasal detection of erythrocytes or their degradation products (Type A: point-like microbleeding, Type B: larger confluent bleeding)	Usually absent
<b>Elongation</b>	Increased length of the capillaries by 50 % or 350 $\mu\text{m}$	Usually absent
<b>Ramification</b>	Abnormal connections between afferent and efferent portion or e.g. tortuous, branching, bushy or coiled	Absent
<b>Capillary loss</b>	Multifocal (avascular areas) or diffuse loss of capillaries	Absent
<b>Pericapillary oedema</b>	Pericapillary increase in interstitial fluid	Absent

**Table 1** Parameters and morphologic findings in capillaroscopy [15,19, 20,21]

Parameter	Standard values (SI units)
C-Reactive Protein (CRP)	< 0,005 g/l
Von Willebrand factor	50-160%
Fibrinogen	150-350 mg/dl
Leukocytes	4 - 10 x 10 <sup>9</sup> /l
Blood sedimentation	0–20 mm/h
D-Dimer	≤ 300 µg/l
Total Cholesterol (TC)	3,88–5,15 mmol/l
Triglycerides	< 2,82 mmol/l
High-Density-Lipoprotein cholesterol (HDL-C)	≥ 1,04 mmol/l
Low-Density-Lipoprotein cholesterol (LDL-C)	≤ 3,36 mmol/l

**Table 2** Circulating markers of endothelial damage and inflammation

### Statistical considerations

This is a first exploratory study investigating capillary pathologies by DVNC in patients with psoriasis vulgaris since there is only little a-priori knowledge about the frequency and extent of morphological changes of nailfold capillaries in patients with psoriasis vulgaris. Thus, a formal sample size calculation is not possible. This exploratory study will provide the necessary prerequisites for a formal sample size calculation for a full-scale study.

A total of 100 complete and evaluable datasets will allow obtaining a first impression of the potential impact of psoriasis on capillary pathologies by descriptive statistics. It is planned to investigate 50 patients with psoriasis vulgaris alone or psoriasis vulgaris accompanied by psoriasis arthritis and to compare the results to 50 healthy subjects. The resulting group allocation is sufficient to determine an effect size of 0.7 (Cohen's d) with a t test at 5% significance level and 80% power. Taking into account a dropout rate of 20%, at least 127 patients shall be recruited. All endpoints will be analyzed descriptively by tabulation of the measures of the empirical distributions. Depending on the scale level of the variables, means, standard deviations, medians, and first and third quartiles, as well as either minimum and maximum or absolute and relative frequency, will be reported. Descriptive p-values of the corresponding statistical tests comparing results of patients to healthy subjects will be given, together with the associated 95% confidence intervals. When appropriate, graphical methods will be used to visualize the findings.

## **Ethical considerations, dissemination plan and regulatory obligations**

The study is conducted in accordance with the Declaration of Helsinki principles (2013), applicable local government regulations, and independent Ethics Committee policies and procedures. Before initiation of the study, the protocol was presented and approved by the independent ethics committee of the medical faculty of the University of Heidelberg (Ethics approval number S-447/2017). The design and the final results of the study will be presented at meetings and congresses, will be published in written form in international scientific journals.

## **Recruitment and status of the study**

Ethical approval was granted in September 2017. Planned date of first enrollment is July 2018. The estimated time required for recruitment of 96 patients is 12 months. The total duration of the study is expected to be 24 months, including statistical analysis.

## **Patient and public involvement**

Patients or public were not involved in the design or conduct of the study. . Study results will be made available to the public via press releases as launched by the media departments of the authors' institutions.

## **FOOTNOTES**

### **Funding statement**

This work was supported by a grant from Novartis Pharma GmbH, Nürnberg, Germany.

### **Study registration**



This study was registered at the German Clinical Trial Register (DRKS): DRKS00012856 (<https://www.germanctr.de/>).

### Conflicts of interest

The authors declared that they have no competing interests.

### Authors' contribution

C. Fink, S. Kilian, I. Bertlich, E. Hoxha, A. Enk and H.A. Haenssle participated in the development and the implementation of the study (writing of the protocol, submission to ethics committee, data management). C. Fink, S. Kilian, I. Bertlich, E. Hoxha, F. Bardehle, A. Enk and H.A. Haenssle helped to draft and to review the paper. All authors read and approved the final manuscript.

### REFERENCES

1. Smith V, Thevissen K, Trombetta AC, et al. Nailfold capillaroscopy and clinical applications in systemic sclerosis. *Microcirculation* 2016;23:364–372.
2. Martínez-Sales V, Vila V, Ricart JM. Increased circulating endothelial cells and microparticles in patients with psoriasis. *Clin Hemorheol Microcirc.* 2015;60(3):283-90.
3. Hofstee HM, Vonk Noordegraaf A, Voskuyl AE, et al. Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis. *Ann Rheum Dis* 2009;68:191–5
4. Nast A, Boehneke WH, Mrowietz U, et al. S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update. *J Dtsch Dermatol Ges* 2012;10:S1–s95



- 1  
2  
3 5. Gyldenløve M, Jensen P, Løvendorf MB et al. 'Short-term treatment with methotrexate does not  
4 affect microvascular endothelial function in patients with psoriasis'. *J Eur Acad Dermatol Venereol*  
5 2015;29:591–594.  
6
- 7  
8  
9 6. Gonzalez-juanatey C, Llorca J, Amigo-Diaz E, et al. High prevalence of subclinical atherosclerosis  
10 in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis  
11 risk factors. *Arthritis & Rheumatism* 2007;57:1074–1080  
12
- 13  
14  
15 7. Pirro M, Stingeni L, Vaudo G et al. Systemic inflammation and imbalance between endothelial  
16 injury and repair in patients with psoriasis are associated with preclinical atherosclerosis. *Eur J Prev*  
17 *Cardiol* 2015;22(8):1027-35  
18
- 19  
20  
21 8. Barton SP, Abdullah MS, Marks R. Quantification of microvascular changes in the skin in patients  
22 with psoriasis. *Br J Dermatol* 1992;126:569±74.  
23
- 24  
25  
26 9. Espinoza LR, Vasey FB, Espinoza CG et al. Vascular changes in psoriatic synovium. A light and  
27 electron microscopic study. *Arthritis Rheum* 1982;25:677±84  
28
- 29  
30  
31 10. Redisch W, Messina EJ, Hughes G, et al. Capillaroscopic observations in rheumatic diseases. *Ann*  
32 *Rheum Dis* 1970;29:244±53  
33
- 34  
35  
36 11. Zaric D, Clemmensen OJ, Worm AM, et al. Capillary microscopy of the nail fold in patients with  
37 psoriasis and psoriatic arthritis. *Dermatologica* 1982;164:10±14  
38
- 39  
40  
41 12. Ohtsuka T, Yamakage A, Miyachi Y. Statistical definition of nailfold capillary pattern in patients  
42 with psoriasis. *Int J Dermatol* 1994;33:779±82  
43
- 44  
45  
46 13. Ribeiro CF Siqueira EB, Holler AP et al. Periungual capillaroscopy in psoriasis. *An Bras Dermatol*  
47 2012;87(4):550-3.  
48
- 49  
50  
51 14. Bhushan M, Moore T, Herrick AL et al. Nailfold video capillaroscopy in psoriasis. *Br J Dermatol*  
52 2000;142(6):1171-6  
53
- 54  
55  
56 15. Cutolo M, editor. Atlas of capillaroscopy in rheumatic diseases. Milano: Elsevier Srl; 2010.  
57

- 1  
2  
3 16. Sander O, Sunderkötter C, Kötter I et al. Kapillarmikroskopie Durchführung und Nomenklatur. *Z*  
4  
5 *Rheumatol* 2010;69:253–62.  
6  
7  
8 17. Smith V, Pizzorni C, De Keyser F, et al. Reliability of the qualitative and semiquantitative  
9  
10 nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. *Annals of*  
11  
12 *the Rheumatic Diseases* 2010;69:1092-1096.  
13  
14 18. Smith V, Beeckman S, Herrick AL et al. An EULAR study group pilot study on reliability of  
15  
16 simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases.  
17  
18 *Rheumatology*, Volume 55, Issue 5, 1 May 2016, Pages 883–890  
19  
20  
21 19. Klein-Weigel PF, Sunderkötter C, Sander O. Nailfold capillaroscopy microscopy - an  
22  
23 interdisciplinary appraisal. *Vasa* 2016;45(5):353-64.  
24  
25  
26 20. Jung, P, Trautinger, F. Capillaroscopy. *J Dtsch Dermatol Ges* 2013;11:731–736.  
27  
28  
29 21. Chojnowski MM, Felis-Giemza A, Olesińska M. Capillaroscopy – a role in modern rheumatology.  
30  
31 *Reumatologia*. 2016;54(2):67-72.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**FIGURE Legend**

**Figure 1** Flowchart of the study

For peer review only




Figure 1 Flowchart of the study

52x61mm (300 x 300 DPI)